Barclays’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-10,400
Closed -$79K – 5516
2020
Q1
$79K Buy
10,400
+10,200
+5,100% +$79.4K ﹤0.01% 4945
2019
Q4
$1K Hold
200
– – ﹤0.01% 6263
2019
Q3
$1K Buy
+200
New +$857 ﹤0.01% 6568
2019
Q1
– Sell
-4,811
Closed -$27K – 6976
2018
Q4
$27K Buy
+4,811
New +$37.6K ﹤0.01% 5766

Other funds holding AKBA

Barclays's AKBA Position: Q3 2026 in Review

Barclays increased its Akebia Therapeutics (AKBA) stake by 21% in Q3 2026, buying an estimated $29K and bringing the position to 155,290 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.

Barclays first reported a position in AKBA in Q2 2014 and has held it in 43 quarters since. The position peaked at $3.58M in Q2 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Barclays held 155,290 shares of Akebia Therapeutics worth $143K as of Q3 2026.
  • Barclays bought 26,932 Akebia Therapeutics shares in Q3 2026, an estimated $29K.
  • Akebia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4159 holding.
  • Barclays first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 43 quarters since.
  • Barclays's Akebia Therapeutics position peaked at $3.58M in Q2 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.